Skip to main content
Download PDF

Rates of pneumonia among children and adults with chronic medical conditions in Germany

BMC Infectious Diseases volume 15, Article number: 470 (2015) Cite this article

Abstract

Background

The objective of this study is to evaluate rates of all-cause pneumonia among “at-risk” and “high-risk” children and adults in Germany—in comparison with age-stratified healthy counterparts—during the period following the 2006 recommendation for universal immunization of infants with pneumococcal conjugate vaccine.

Methods

Retrospective cohort design and healthcare claims information for 3.4 M persons in Germany (2009–2012) were employed. Study population was stratified by age and risk profile (healthy, “at-risk” [with chronic medical conditions], and “high-risk” [immunocompromised]). At-risk and high-risk conditions, as well as episodes of all-cause pneumonia, were identified via diagnosis, procedure, and drug codes.

Results and discussion

Rates of all-cause pneumonia were 1.7 (95 % CI 1.7-1.8) to 2.5 (2.4-2.5) times higher among children and adults with at-risk conditions versus healthy counterparts, and 1.8 (1.8-1.9) to 4.1 (4.0-4.2) times higher among children and adults with high-risk conditions. Rates of all-cause pneumonia among at-risk persons increased in a graded and monotonic fashion with increasing numbers of conditions (i.e., risk stacking).

Conclusions

An increased risk for all-cause pneumonia in German children and adults with a spectrum of medical conditions persists in the era of widespread pneumococcal vaccination, and pneumonia risk in persons with ≥2 at-risk conditions is comparable or higher than those with high-risk conditions.

Peer Review reports

Background

Community-acquired pneumonia (CAP) is a frequent cause of hospitalization and death in Germany. The incidence of CAP has been estimated to be 3.7-10.1/1000 inhabitants [1], and over 259,000 German adults were estimated to have been hospitalized for CAP in 2013 [2]. Ewig and colleagues observed that the incidence of CAP increased with advancing age, and that overall in-hospital mortality of CAP patients was 14 %, with the highest mortality in persons with comorbid conditions; among persons with malignancies, dementia, and pulmonary diseases (other than chronic obstructive pulmonary disease [COPD]), mortality was more than two-fold higher than among those with no known underlying conditions. Importantly, mortality risk was highest in the first days after admission, suggesting that prevention strategies may be more important than therapeutic approaches to reduce mortality [3].

Streptococcus pneumoniae (pneumococcus) has been reported to be one of the most common causes of ambulatory, hospitalized, and severe pneumonia among adults throughout Europe [4, 5]. While it is widely recognized that persons with immunocompromising conditions, as well as those with certain chronic illnesses, were at increased risk of pneumococcal disease prior to the widespread introduction of seven-valent pneumococcal conjugate vaccine (PCV7) in the US and western Europe, recent assessments of disease risk in populations following mass vaccination of children with PCVs are limited. The indirect effect of childhood immunization has led to impressive declines in the incidence of invasive pneumococcal disease in US adults [6–11], but more variable herd effects in western Europe [12]. Further confirmation from additional populations as to the magnitude of the increased risk of pneumococcal disease associated with certain chronic medical conditions following introduction of pneumococcal conjugate vaccines would be valuable for developing future vaccine policies for the prevention of pneumonia.

We therefore employed a large German research database to estimate rates of all-cause pneumonia—as a proxy for pneumococcal disease—among persons with and without one or more of the chronic illnesses included by the German Committee on Vaccination (Ständige Impfkommission [STIKO]) and/or the US Advisory Committee for Immunization Practices (ACIP) as indications for pneumococcal vaccination. We also examined disease rates among persons with other conditions that might increase infection risk based on limited data from other studies, including three autoimmune diseases—rheumatoid arthritis, systemic lupus erythematosus, and Crohn’s disease—as well as neuromuscular (chiefly cerebral palsy)/seizure disorders [13–16]. Finally, we examined the impact of risk stacking among the at-risk population by estimating disease rates within subgroups defined on the basis of the number of concurrent conditions.

Methods

Data design and source

A retrospective cohort design and data from the Health Risk Institute (HRI) Research Database spanning 2008–2012 were employed. The HRI Database comprises medical and drug claims from an age and gender representative sample of 3.4 million persons covered by the statutory health care system in Germany, approximately 4 % of the total population. The HRI Scientific Board approved our study and granted access to the HRI Research Database.

Data available from each medical claim include date/quarter of service, place of service, diagnoses (International Statistical Classification of Diseases and Related Health Problems, 10th revision, German Modification [ICD-10-GM]), procedures performed/services rendered, and quantity of services. Data available for each drug claim include the agent dispensed (as set forth by the Anatomical Therapeutic Chemical [ATC] System), dispensing/prescription date, and quantity dispensed. Medical and drug claims also include amounts paid (i.e., reimbursed) to providers by health insurers. Selected demographic and eligibility information (including age/year of birth, sex, dates of enrollment) also is available for persons in the HRI Database. All data can be arrayed to provide a detailed chronology of medical and pharmacy series used by each insured member over time.

Insurance benefits extend to all healthcare services. The HRI Database does not include data on clinical parameters (e.g., lab results), quality of life, or markers of disease severity because health insurers in Germany are prohibited by federal law from having such information. All patient-level data in the HRI Research Database are de-identified to comply with German data protection regulations. Use of the study database for health services research is therefore fully compliant with German federal law and, accordingly, IRB/ethical approval was not needed.

Study population

The study population comprised persons who were enrolled in a health insurer represented in the HRI Database on January 1, 2009. Persons who were not continuously eligible for health insurance benefits for at least one year prior to January 1, 2009 were excluded from the study population; less than 0.5 % of the population from the HRI Database was excluded due to this criterion. Infants <12 months of age as of this date were not subject to this exclusionary criterion.

Study subjects were stratified based on their age (<5, 5–17, 18–49, 50–59, and ≥60 years) and risk profile (“at-risk”, “high-risk”, and “healthy”). Risk profiles were defined based on the presence of medical conditions that are indications for pneumococcal vaccination among children and adults including alcoholism, asthma, chronic heart disease, chronic liver disease, chronic lung disease, chronic renal failure, cochlear implant, Crohn’s disease, diabetes, Down’s syndrome, functional/anatomic asplenia, HIV, immunosuppressant therapy, short gestation/low birthweight, smoking, as well as those medical conditions hypothesized to be associated with increased risk including neuromuscular/seizure disorders, rheumatoid arthritis, and systemic lupus erythematosis [13–16]. The list of medical conditions was based on recommendations for vaccination set forth by STIKO and/or ACIP, as well as other conditions previously reported to confer an increased risk of pneumococcal disease.

Immunocompetent persons with ≥1 chronic medical condition were classified as at-risk; immunocompromised/immunosuppressed persons and those with a cochlear implant were classified as high-risk. At-risk and high-risk were mutually exclusive categories and thus, for example, persons considered immunosuppressed due to cancer treatment were included in the high-risk category only, even if they also had an at-risk condition. Persons without evidence of at-risk or high-risk conditions were classified as healthy. At-risk and high-risk medical conditions were ascertained using ICD-10-GM diagnosis codes recorded any time prior to the beginning of the 2009 calendar year. Operational algorithms employed to identify at-risk and high-risk conditions are available in Additional file 1: Table S1 and Additional file 2: Table S2, respectively, of the online supplement.

Study measures

Episodes of all-cause pneumonia (i.e., all clinical cases caused by all known and unknown pathogens, including S. pneumoniae) were identified during the four-year period beginning on January 1, 2009 and ending on December 31, 2012 or the date of health insurer disenrollment, whichever occurred first. Episodes were identified using operational algorithms based on corresponding diagnosis codes (ICD-10-GM) in the principal or secondary position, procedure codes for inpatient care (Operationen- und Prozedurenschlüssel [OPS]), and ATC drug codes, as set forth in the online supplement (Additional file 3: Table S3); cases that were invasive (i.e., bacteremic) in nature were excluded from consideration. Multiple episodes of all-cause pneumonia for a given patient were included as independent events if they were separated by ≥90 days.

Statistical analyses

Incidence rates of all-cause pneumonia episodes were estimated for children and adults within each age group by risk profile as well as individual medical condition, and were expressed per 100,000 person-years. Rate ratios for disease episodes among persons with at-risk and high-risk conditions, respectively—overall and by individual medical condition—versus their age-stratified healthy counterparts were estimated using Poisson regression (SAS v 9.3). Rates of disease and corresponding rate ratios (vs. healthy counterparts) also were calculated for at-risk persons by the number of at-risk conditions.

Results

Children

Characteristics

Children aged <5 years and 5–17 years contributed a total of 0.5 million and 1.7 million person-years of observation, respectively. In these two age groups, 71 % and 79 %, respectively, had none of the selected chronic or immunocompromising conditions, 26 % and 19 % had ≥1 at-risk condition (and no high-risk conditions), and 3 % and 2 % had a high-risk condition.

Among those with at-risk conditions, chronic lung disease (68 % and 54 %) and asthma (23 % and 43 %) were common; 17 % of children <5 years of age and 13 % of children 5–17 years of age with at-risk conditions had more than one condition.

Disease rates

Rates of all-cause pneumonia among children <5 years and 5–17 years of age with at-risk conditions were 1.7 (95 % confidence interval [CI] 1.7-1.8) and 2.4 (2.3-2.5) times the rates in their healthy counterparts, and rates of all-cause pneumonia among high-risk children in these age groups were 1.8 (1.8-1.9) and 2.9 (2.8-3.0) times the rates in children without at-risk or high-risk conditions (Table 1). Rate ratios for all-cause pneumonia among children with at-risk conditions increased with the number of such conditions compared with healthy counterparts (Fig. 1). Among younger children, rate ratios increased from 1.5 (1.5-1.5) for those with one condition to 4.7 (4.6-4.7) for those with ≥3 conditions; among older children, rate ratios increased from 2.0 (1.9-2.1) to 11.3 (11.0-11.5).

Table 1 Rates of all-cause pneumonia among healthy, at-risk, and high-risk children
Full size table
Fig. 1
figure 1

Rates of all-cause pneumonia among children by number of risk conditions

Full size image

Adults

Characteristics

Persons aged 18–49 years, 50–59 years, and ≥60 years contributed a total of 5.7 million, 2.0 million, and 3.5 million person-years of observation, respectively. Approximately 76 %, 60 %, and 36 %, respectively, had none of the selected chronic or immunocompromising conditions. The prevalence of at-risk and high-risk conditions increased with increasing age: 21 %, 33 %, and 45 % had at-risk conditions, and 3 %, 7 %, and 19 % had high-risk conditions.

Among adults aged 18–49 years with at-risk conditions, the most common conditions were chronic lung disease (48 %), asthma (27 %), and chronic liver disease (13 %). In adults 50–59 years of age, the most common conditions were chronic lung disease (37 %), diabetes (26 %), chronic liver disease (24 %), and chronic heart disease (23 %). In adults ≥60 years of age, the most common conditions were chronic heart disease (46 %), diabetes (41 %), chronic lung disease (30 %), and chronic liver disease (20 %).

Disease rates

Adults aged 18–49, 50–59, and ≥60 years with at-risk conditions had 2.2 (2.1-2.4), 2.3 (2.2-2.4), and 2.5 (2.4-2.5) times the rates of all-cause pneumonia as their healthy counterparts (Table 2). Corresponding rate ratios for those with high-risk conditions were 3.2 (3.0-3.4), 3.7 (3.6-3.9), and 4.1 (4.0-4.2).

Table 2 Rates of all-cause pneumonia among healthy, at-risk, and high-risk adults
Full size table

Rate ratios for all-cause pneumonia among adults with at-risk conditions increased with the number of such conditions compared with healthy counterparts (Fig. 2). Rates among adults with two at-risk conditions were generally similar to rates among adults with high-risk conditions, and rates in adults with three or more at-risk conditions were higher than those among adults with high-risk conditions. Rates and rate ratios of all-cause pneumonia among healthy, at-risk, and high-risk adults stratified by additional age groups are available in Additional file 4: Table S4 of the online supplement.

Fig. 2
figure 2

Rates of all-cause pneumonia among adults by number of risk conditions

Full size image

Discussion

We undertook a large retrospective evaluation of rates of all-cause pneumonia among “at-risk” and “high-risk” children and adults in Germany—in comparison with age-stratified healthy counterparts—in the period following the 2006 recommendation for universal immunization of infants with pneumococcal conjugate vaccine. The results of this evaluation suggest that immunocompetent persons with comorbid conditions and immunocompromised persons of all ages continue to suffer a disproportionate burden of pneumonia in the era of widespread pneumococcal vaccination [3, 17–21]. Both the proportion of the German population with an at-risk or high-risk condition and the incidence of CAP are reported to climb with increasing age. Moreover, the results of this study suggest that the risk of all-cause pneumonia among children and adults with ≥2 at-risk conditions is comparable to, or exceeds, corresponding values among age-stratified persons with high-risk conditions. Our data also provide additional evidence in support of an increased risk of all-cause pneumonia in adults with rheumatoid arthritis, systemic lupus erythematosus, Crohn’s disease, and neuromuscular/seizure disorders [13, 22]. Such conditions are not currently included within the STIKO or ACIP recommendations for prevention.

Notwithstanding differences in study design and methods between our evaluation and work by Ewig and colleagues—including their use of records from all hospitals in Germany (vs. claims information from an age/gender-representative sample in our study), their focus on an adult population (vs. children and adults), and their focus on inpatient CAP (vs. inpatient and outpatient all-cause pneumonia)—the results of our study are largely consistent with their findings. Ewig et al. identified cardiac, central nervous system, and pulmonary disease (other than COPD), as well as diabetes and COPD, as the five most prevalent comorbid conditions in adults with hospitalized CAP. Similarly, we found chronic lung disease, chronic heart disease, and diabetes to be the most prevalent chronic diseases among Germans with all-cause pneumonia; asthma and chronic liver disease also were found to be common among pneumonia cases.

Recent studies from the UK and US found that the elevated risk of pneumonia in adults with selected medical conditions persisted during the era following the introduction of pneumococcal conjugate vaccine, although the magnitude of relative risk was not always consistent [13, 22–24]. In our study, German children under the age of 5 years with at-risk conditions accounted for 26 % of this age cohort yet 36 % of all-cause pneumonia cases; children aged 5–17 years with at-risk conditions accounted for 19 % of this cohort but 34 % of all-cause pneumonia cases. Comparable results for adults aged <60 years were: 18–49 year-olds, 21 % of the cohort and 35 % of disease burden; 50–59 year-olds, 33 % of the cohort and 47 % of disease burden. Consistent with published data from Shea and colleagues, we found increasing incidence of pneumonia with increasing age in at-risk, high-risk, and healthy persons, and relatively stable rate ratios, suggesting that the relative increase in disease risk with age is similar in all three groups [13].

We chose all-cause pneumonia as a proxy for pneumococcal pneumonia based on several considerations. First, studies in children demonstrate that identification of pneumococcus as a cause of hospitalized pneumonia substantially underestimates the role of pneumococcus compared to the reduction in all-cause hospitalized pneumonia achieved following introduction of pneumococcal conjugate vaccine [25, 26]. We believe the same challenge would be relevant for the diagnosis of pneumococcal pneumonia in adults in clinical settings. Moreover, operational algorithms for pathogen-specific cases of pneumonia based on diagnosis codes typically lack adequate sensitivity since diagnostic tests (i.e., culture, serological, and polymerase chain reaction [PCR] tests, as well as invasive sampling methods) are infrequently performed in clinical practice. Thus, in the absence of concurrent bacteremia, the diagnosis (and therefore coding) of pneumococcal pneumonia underestimates disease burden. Second, in the control group in the CAPiTA study, 22 % (174 of 787) of episodes of CAP in adults ≥65 years of age were due to vaccine serotypes representing a minimum estimate of pneumococcal burden in this age group as nonvaccine serotypes were not sought. Lastly, in the retrospective study by Shea and colleagues based on US healthcare claims data, the increased disease risk in “at-risk” and “high-risk” subjects was comparable for both all-cause pneumonia and pneumococcal pneumonia [13].

We note several other limitations that are inherent in the use of healthcare claims data for retrospective studies such as this one. First, rates of all-cause pneumonia may be misestimated somewhat due to the less than perfect sensitivity and specificity of our case-ascertainment algorithm. However, to the extent this limitation impacts rates in a proportional manner across age and risk groups, rate ratios should be largely unaffected. Second, use of operational algorithms and the left-truncation of the study database undoubtedly resulted in the misclassification of risk profiles for some persons, including both errors of omission and commission. For example, diagnosis codes capturing smoking and alcoholism are under-recorded in the study database, and procedures (e.g., cochlear implant) performed prior to the beginning of the study database were not observable. Unfortunately, it was not possible to undertake a formal evaluation—for example, via chart review or use of additional data sources (e.g., electronic medical records)—of the accuracy of these algorithms within the context of this study. Third, data limitations precluded us from identifying the specific pathogen/serotype causing disease; it would be of interest to know the proportion of cases due to individual pathogens/serotypes, and whether or not they are included in PCV7, PCV10, PCV13, and PPSV23 (or currently unavailable vaccines). Fourth, to the extent pneumococcal vaccination status varies by risk profile (i.e., likely to be higher uptake among high-risk and at-risk persons vs. healthy persons), rate ratios may be downwardly biased. Fifth, while the HRI Database comprises claims data from individuals covered by the German statutory health care system and is representative of the German population in terms of age and gender, it is unknown whether the HRI Database is representative of the German population in terms of race, socio-economic factors, and other such characteristics. Finally, while the HRI Research Database should be sufficiently large to compare (robustly) rates of disease between age-specific at-risk and high-risk persons versus their healthy counterparts, comparisons of rates within subgroups defined on the basis of individual conditions are undoubtedly underpowered in many instances and should be interpreted with caution.

Conclusion

Our data confirm previous reports of enhanced risk in individuals with multiple comorbid conditions [13, 22, 27]. Expanded use of pneumococcal conjugate vaccines have been proposed to prevent pneumococcal pneumonia in high-risk individuals and those 65 years of age and older. In conjunction with recent publications [11, 13, 22, 23, 28], our findings suggest that the highest rates of all-cause pneumonia, and presumably pneumococcal pneumonia, occur in individuals with multiple comorbid conditions in the absence of immune deficiency. In adults with traditional high-risk conditions, high mortality rates have been reported [3]. If high mortality rates from all-cause pneumonia and pneumococcal pneumonia also are observed in individuals with multiple at-risk conditions in the absence of immune compromise, further effort to understand the underlying susceptibility could lead to additional strategies for prevention.

Abbreviations

ATC:

Anatomic Therapeutic Chemical

COPD:

Chronic obstructive pulmonary disease

CAP:

Community-acquired pneumonia

HRI:

Health Risk Institute

ICD-10-GM:

International Statistical Classification of Diseases and Related Health Problem, 10th revision, German Modification

OPS:

Operationen- und Prozedurenschlüssel

OPS:

Polymerase Chain Reaction

PCR:

Pneumococcal conjugate vaccine

PCV7:

Seven-valent pneumococcal conjugate vaccine

STIKO:

Ständige Impfkommission

pneumococcus:

Streptococcus pneumoniae

PCV10:

Ten-valent pneumococcal conjugate vaccine

PCV13:

Thirteen-valent pneumococcal conjugate vaccine

PPSV23:

Twenty-three-valent pneumococcal polysaccharide vaccine

ACIP:

US Advisory Committee for Immunization Practices

References

  1. Schnoor M, Hedicke J, Dalhoff K, Raspe H, Schäfer T, CAPNETZ study group. Approaches to estimate the population-based incidence of community acquired pneumonia. J Infect. 2007;55(3):233–9.

    Article  PubMed  Google Scholar 

  2. AQUA Institut GmbH, Bundesauswertung 2013, PNEU–Ambulant erworbene Pneumonie Qualitaetsingikatoren. 2014

  3. Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009;64:1062–9. doi:10.1136/thx.2008.109785.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71–9.

    Article  CAS  PubMed  Google Scholar 

  5. Rozenbaum MH, Pechlivanoglou P, van der Werf TS, Lo-Ten-Foe JR, Postma MJ, Hak E. The role of streptococcus pneumonia in community-acquired pneumonia among adults in Europe: a meta-analysis. Eur J Clin Microbiol Infect Dis. 2013;32(3):305–16.

    Article  CAS  PubMed  Google Scholar 

  6. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179–86.

    Article  CAS  PubMed  Google Scholar 

  7. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infec Dis. 2007;196:1346–54.

    Article  Google Scholar 

  8. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294:2043–51.

    Article  CAS  PubMed  Google Scholar 

  9. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32–41.

    Article  PubMed  Google Scholar 

  10. Moore M, Link-Gelles R, Farley MM, Schaffner W, Thomas A, Reingold A, et al. Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease, US 2010–11, oral presentation at ID Week. 2012.

    Google Scholar 

  11. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. US hospitalizations for pneumonia after a decade of pneumococcal vaccination. NEJM. 2013;369(2):155–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10):760–8.

    Article  CAS  PubMed  Google Scholar 

  13. Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1). doi:10.1007/s00431-014-2409-0

  14. Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health. 2012;66(12):1177–81.

    Article  PubMed  Google Scholar 

  15. Vinogradova Y, Hippisley-Cox J, Coupland C. Identification of new risk factors for pneumonia: population-based case–control study. Br J Gen Pract. 2009;59(567):e329–38.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Bhat N, Wright JG, Broder KR, Murray EL, Greenberg ME, Glover MJ, et al. Influenza-associated deaths among children in the United States, 2003–2004. N Engl J Med. 2005;353(24):2559–67.

    Article  CAS  PubMed  Google Scholar 

  17. van der Linden M, Imöhl M, Busse A, Rose M, Adam D. Bacterial sprectrum of spontaneously ruptured otitis media in the era of pneumococcal conjugate vaccination in Germany. Eur J Pediatr. 2014. doi:10.1007/s00431-014-2409-0.

    Google Scholar 

  18. van der Linden M, Perniciaro S, Imöhl M. Effects of 5 years of immunization with higher valent pneumococcal conjugate vaccines in German children. Dublin: Poster presented at European Society for Paediatric Infectious Diseases; 2014.

    Google Scholar 

  19. van der Linden M, Weiss S, Falkenhorst G, Siedler A, Imöhl M, von Kries R. Four years of universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive pneumococcal disease and serotype distribution in children. Vaccine. 2012;30:5880–5.

    Article  PubMed  Google Scholar 

  20. Laurenz M, Sprenger R, von Eiff C, Busse A. Reduced incidence of otitis media among children in Germany after introduction of higher-valent pneumococcal conjugate vaccines. Dublin: Poster presented at European Society for Paediatric Infectious Diseases; 2014.

    Google Scholar 

  21. Laurenz M, Sprenger R, von Eiff C, Busse A. Reduced incidence of pneumonia among children in Germany after introduction of higher-valent pneumococcal conjugate vaccines. Dublin: Poster presented at European Society for Paediatric Infectious Diseases; 2014.

    Google Scholar 

  22. Pelton SI, Weycker D, Farkouh RA, Strutton DR, Shea KM, Edelsberg J. Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine. Clin Infect Dis. 2014;59(5):615–23.

    Article  PubMed  Google Scholar 

  23. Muhammad RD, Oza-Frank R, Zell E, Link-Gelles R, Narayan KM, Schaffner W, et al. Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clin Infect Dis. 2013;56(5):e59–67.

    Article  CAS  PubMed  Google Scholar 

  24. van Hoek AJ, Andrews N, Waight P, Stowe J, Gates P, George R, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65(1):17–24.

    Article  PubMed  Google Scholar 

  25. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. NEJM. 2015;372(9):45.

    Article  Google Scholar 

  26. Griffin MR, Mitchel E, Moore MR, Whitney CG, Grijalva CG, Centers for Disease Control and Prevention (CDC). Declines in pneumonia hospitalization of children aged <2 years associated with the use of pneumococcal conjugate vaccine – Tennessee, 1998–2012. MMWR. 2014;63(44):995–8.

    PubMed  PubMed Central  Google Scholar 

  27. Pelton SI, Shea KM, Weycker D, Farkouh RA, Strutton DR, Edelsberg J. Rethinking risk for pneumococcal disease in adults: The role of risk stacking. Open Forum Infect Dis. 2015. [Epub ahead of print].

  28. Yildirim I, Shea KM, Little BA, Silverio AL, Pelton SI. Vaccination, underlying comorbidities, and risk ofinvasive pneumococcal disease. Pediatrics. 2015; 135(3):495-503. doi:10.1542/peds.2014-2426. Epub 2015 Feb 2.

Download references

Acknowledgements

The study sponsor, Pfizer Inc., reviewed the study research plan and study manuscript; data management, processing, and analyses were conducted by PAI and Xcenda in cooperation with Elsevier Health Analytics, and all final analytic decisions were made by study investigators. Stephen I. Pelton confirms that he had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Author information

Authors and Affiliations

  1. Boston University School of Public Health, Boston, MA, USA

    Stephen I. Pelton & Kimberly M. Shea

  2. Boston Medical Center, Boston, MA, USA

    Stephen I. Pelton

  3. Pfizer Inc., Collegeville, PA, USA

    Raymond A. Farkouh & David R. Strutton

  4. Xcenda GmbH, Hannover, Germany

    Sebastian Braun & Christian Jacob

  5. Pfizer bv, Capelle a/d IJssel, Netherlands

    Rogier Klok

  6. Policy Analysis Inc. (PAI), Brookline, MA, USA

    Elana S. Gruen & Derek Weycker

  7. Maxwell Finland Laboratory for Infectious Diseases, 670 Albany Street, 6th Floor, Boston, MA, 02118, USA

    Stephen I. Pelton

Authors
  1. Stephen I. Pelton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kimberly M. Shea
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raymond A. Farkouh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David R. Strutton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sebastian Braun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christian Jacob
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rogier Klok
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Elana S. Gruen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Derek Weycker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen I. Pelton.

Additional information

Competing interests

Funding for this research was provided by Pfizer Inc. to Policy Analysis Inc. (PAI) and Xcenda GmbH.

Authors’ contributions

Authorship was designated based on guidelines promulgated by the International Committee of Medical Journal Editors (2004). All persons who met criteria for authorship were listed as authors on the title page. RAF, RK, SIP, DRS, and DW contributed to the conception and design of the study, SB and CJ acquired the data, and all authors participated in analysis or interpretation of the data. ESG, SIP, and DW prepared the manuscript, and SB, RAF, CJ, RK, KMS, and DRS provided critical review. All authors have read and approved the final version of the manuscript.

Additional files

Additional file 1: Table S1.

Diagnosis, procedure, and drug codes for algorithms identifying at-risk conditions. (DOC 91 kb)

Additional file 2: Table S2.

High risk-conditions: Diagnosis, procedure, and drug codes for algorithms identifying baseline risk factors and study measures. (DOC 70 kb)

Additional file 3: Table S3.

Outcome: Diagnosis, procedure, and drug codes for algorithms identifying all-cause pneumonia *. (DOC 97 kb)

Additional file 4: Table S4.

Rates of all-cause pneumonia among healthy, at-risk, and high-risk adults, by age. (DOC 941 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pelton, S.I., Shea, K.M., Farkouh, R.A. et al. Rates of pneumonia among children and adults with chronic medical conditions in Germany. BMC Infect Dis 15, 470 (2015). https://doi.org/10.1186/s12879-015-1162-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12879-015-1162-y

Keywords

BMC Infectious Diseases

ISSN: 1471-2334

Contact us